| 货号 | 规格 | 价格 | 上海 | 北京 | 珠海 | 重庆 | 武汉 | 购买数量 |
|---|---|---|---|---|---|---|---|---|
S89529-5mg促销 |
98.70% | ￥350.00 ￥280.00 |
5 | - | - | - | - |
|
S89529-10mg促销 |
98.70% | ￥570.00 ￥456.00 |
6 | - | - | - | - |
|
S89529-25mg促销 |
98.70% | ￥1150.00 ￥920.00 |
5 | - | - | - | - |
|
S89529-100mg促销 |
≥98% | ￥2830.00 ￥2540.00 |
货期：2-3天 | - | - | - | - |
|
| 产品描述： | CZC-54252 hydrochloride is a selective inhibitor of LRRK2 with IC50s of 1.85 nM and 1.28 nM for wild-type and G2019S LRRK2. CZC-54252 hydrochloride has a neuroprotective activity and attenuates G2019S LRRK2-induced human neuronal injury with an EC50 of 1 nM | ||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 靶点： | G2019S LRRK2:1.85 nM (IC50), Wild-type LRRK2:1.28 nM (IC50);LRRK2 | ||||||||||||||||||||
| 体外研究： | CZC-54252 hydrochloride(1.6 nM) fully reverses G2019S LRRK2-induced human neuronal injury to wild-type levels. CZC-54252 hydrochloride inhibits the recombinant human wild-type LRRK2 with an IC50 ranging from 1 to 5 nM. CZC-54252 hydrochloride inhibits the G2019S mutant with an IC50 ranging from 2 to 7 nM in a TF-FRET assay | ||||||||||||||||||||
| 参考文献： | 1. Nigel Ramsden, et al. Chemoproteomics-based design of potent LRRK2-selective lead compounds that attenuate Parkinson's disease-related toxicity in human neurons. ACS Chem Biol. 2011 Oct 21;6(10):1021-8. 2. Ramsden N, et al. Chemoproteomics-based design of potent LRRK2-selective lead compounds that attenuate Parkinson's disease-related toxicity in human neurons. ACS Chem Biol. 2011 Oct 21;6(10):1021-8. | ||||||||||||||||||||
| 溶解性： | Soluble in DMSO | ||||||||||||||||||||
| 保存条件： | -20℃ | ||||||||||||||||||||
| 配置溶液浓度参考： |
|
||||||||||||||||||||
| 注意： | 部分产品我司仅能提供部分信息，我司不保证所提供信息的权威性，仅供客户参考交流研究之用。 |
上海工商
沪公网安备 31011702002021号
危险品化学品经营许可证（不带存储）
营业执照(三证合一)
北京